Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Cisplatin, and Bevacizumab in Metastatic Pancreatic Cancer
NCT00126633Phase 2Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2004
- Primary completion
- Sep 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in pancreatic cancer (PC), sponsored by University of California, San Francisco. Primary endpoints: Time to Progression, Duration of Response and 3 more. Started Apr 2004; status: completed.
02
Drugs
bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00126633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00126633.